If you don't understand one of the words in this article, just double-click it.
A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature
doesn't work in your browser, you can enter the word below:
Confirmation of Tesamorelin’s Lipo-Fighting Potential
Treatment with a synthetic human growth hormone-releasing factor, tesamorelin, resulted in a significant loss of visceral adipose tissue—deep belly fat—compared with a placebo in people with lipodystrophy, according to a press release by the drug’s developer, Theratechnologies. These data come from the first half of a second confirmatory phase 3 clinical trial of the drug and are similar to results seen in the first trial reported in December 2007.
The reported tesamorelin study is a 52-week trial. During the first 26 weeks, approximately two thirds of the patients received tesamorelin and one third received a placebo. During the second 26 weeks of the study, those who originally received the placebo are switched to tesamorelin, while those who originally received tesamorelin will either stay on the drug or be switched to placebo.
Theratechnologies presented the 26-week results earlier this week at the 90th annual meeting of the Endocrine Society in San Francisco. After six months in the study, those who received tesamorelin had an 11 percent decrease in visceral adipose tissue compared with a 1 percent decrease in those who received a placebo. There was no difference in the incidence of serious side effects between those receiving tesamorelin or placebo.
